Microdosing testosterone for TRT: smart protocol or wellness hype?

What did @drstevensorr actually say?

Dr. Sorr argues that standard once- or twice-weekly testosterone injections create large hormonal swings, and that splitting the same total dose into more frequent, smaller injections, what he calls "microdosing," produces a more stable serum level. He frames the benefit mainly around reducing conversion to estrogen via aromatization in adipose tissue and limiting DHT conversion that could cause hair loss, acne, and prostate enlargement. He also walks through delivery options ranging from injectables to the intranasal Natesto product dosed three times daily, pointing to that as an extreme version of the approach.

He does not quote a specific dose, does not prescribe anything, and grounds the argument in pharmacokinetics rather than anecdote. That is a reasonable starting point. Whether the evidence fully supports his framing is a different question.

Does the science back this up?

Partially, yes. The pharmacokinetic logic is real, but the clinical payoff of frequent low-dose injections over standard protocols is less dramatic than the video implies.

Testosterone cypionate and enanthate have half-lives of roughly 7 to 8 days, which means once-weekly injections do produce measurable peak-to-trough swings. Ramasamy et al. (2014, Journal of Urology) documented that men on weekly injections show significantly higher estradiol peaks shortly after injection, which can contribute to side effects like water retention and mood instability. More frequent injections do flatten that curve. A smaller body of work, including data reviewed by Shoskes et al. (2016, Translational Andrology and Urology), supports twice-weekly or every-other-day subcutaneous injections as a way to reduce hematocrit spikes and estrogen fluctuation without requiring additional aromatase inhibitor use in some patients.

However, there is no large randomized controlled trial directly comparing "microdosed" daily injections to twice-weekly injections on hard outcomes like cardiovascular events, prostate volume, or hair loss rates. The evidence is mostly pharmacokinetic modeling and small observational series, not the kind of data that lets you promise "optimized" wellbeing with confidence.

What did they get wrong (or right)?

He got the core pharmacokinetics right. He got the DHT and aromatization pathways mostly right. But there are two places where he oversimplifies in ways that matter.

First, his claim that testosterone converts to estrogen "via the belly fat" is accurate but incomplete. Aromatase is expressed in adipose tissue throughout the body, not uniquely in abdominal fat. Framing it that way implies visceral fat is the main driver, when body fat percentage broadly is what correlates with aromatization rates (Cohen, 2004, Journal of Clinical Endocrinology and Metabolism).

Second, he says DHT is "great for building strong muscle and sexual benefits" but could cause hair loss and acne. This is a fair summary for a short video, but it glosses over the fact that DHT's role in anabolic effects in adults is actually modest compared to testosterone itself. Presenting DHT as primarily a muscle-builder risks overstating its direct benefit while understating the androgenic risk profile.

• Accurate: Peak-trough swings from weekly injections are real and clinically relevant.
• Accurate: More frequent dosing can reduce estradiol spikes in some patients.
• Oversimplified: Aromatization is not specific to belly fat.
• Oversimplified: DHT's role in adult muscle building is secondary, not primary.

What should you actually know?

Frequency of dosing matters, but it is one variable among several, and it is not a substitute for proper monitoring.

If you are on TRT and experiencing side effects like mood swings, elevated estradiol, or erythrocytosis, talking to a clinician about splitting your dose is a reasonable conversation. The evidence supports that frequent subcutaneous injections can smooth out hormonal peaks, and some patients do report fewer side effects. But "microdosing" is not a defined medical term in this context. It is borrowed from psychedelics culture and applied loosely here to mean more-frequent-lower-dose, which is a real protocol but one that requires individualized lab monitoring, not a TikTok optimization tip.

The intranasal option he mentions (Natesto) is FDA-approved and genuinely does produce rapid, short-lived peaks that clear quickly, which is a different pharmacokinetic profile entirely. Research by Ramasamy et al. (2014) showed it preserves sperm production better than injections in some men, which is actually a meaningful clinical distinction he did not mention.

Bottom line: the concept is sound, the evidence is moderate, and anyone considering a dosing change should do it with a prescribing clinician and regular blood work, not a TikTok video as the guide.